GLP-1 drugs shown cost-effective for knee osteoarthritis and obesity A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide
Diabetes UK (2005) Structured patient education in diabetes: report from the Patient Education Working Group
Experienced Doctors: What sets us apart is our highly skilled and experienced doctors spending quality time with you to get to know you and your goals
Only Wegovy and Saxenda have been approved for use as weight-loss medications by Health Canada
The transition point is typically at the 4mg dose level, where a 10mg vial only lasts 2.5 weeks at the rate of 4mg per week
NAD+: The Key to Energy, Longevity, and Cellular Health Feeling fatigued, sluggish, or noticing the effects of aging more than youd like
